SUMMARY The molecular weight distribution of hyaluronate (HA) in synovial fluid (SF) from 10 patients with rheumatoid arthritis (RA), from six patients with other joint disorders, and from five recently deceased persons without joint affections was investigated by a gel chromatographic procedure. A new and highly specific radioassay was used for determination of the HA concentration in the effluent from the chromatographic column, and this allowed analyses on 0-5 ml or less of untreated synovial fluid. The results confirmed the findings by others that the weight-average molecular weight (Mw) of HA in SF from patients with RA (4.8 x 106) was similar to that in other joint diseases (5.0 x 106) and moderately but significantly (p<O.001) lower than that of normal SF (7-0 x 106). Furthermore, the molecular weight distribution of HA in the pathological SF was generally broad and varied considerably between individuals. The HA concentration in the pathological SF varied between 0-17 and 1 -32 g/l, which is in accordance with previous reports and considerably lower than that of normal SF. Neither the nature of the arthropathy and the extent of the inflammatory process nor the pharmacological treatment had a tendency to influence the HA concentration in the SF, the mean molecular weight of HA, or its molecular weight distribution. Although the concentration of HA in SF drops in joint disease, the total amount of the polysaccharide is greatly enhanced. Also the amount of high molecular weight polysaccharide (MW> 6 x 106) is in excess in joint disease. The pathological state is therefore characterised not by lack of high molecular weight hyaluronate but by a dilution of it.
than the SF from the normal knee joint (HA concentration 1-453-12 g/l; HA M, 1-6-10*9 x 106).2 Increased degradation, incomplete synthesis, and increased production of incompletely polymerised HA have been postulated as possible explanations of these observations. [2] [3] [4] Different methods for the estimation of HA concentration and molecular weights have been used. [1] [2] [3] [4] [5] The HA has usually been isolated from the synovial fluid before the analyses, which introduces the uncertainty of incomplete recovery and possible degradation of the polymer. Most The eluent was 0-15 M NaCl/0-02 M Na2BO7 adjusted to pH 11-6. HA in the eluate was determined by radioassay. The recovery in the eluate of the total amount applied was 88 ± 12 (SD) %. The elution profile was translated into a molecular weight distribution with the aid of a calibration 
Discussion
The methodology used in this work has a major advantage over techniques used by other authors, i.e., the analyses can be made on small samples of SF without prior purification of the HA. Furthermore, the gel chromatographic technique gives the complete molecular weight distribution, whereas other techniques only produce average molecular weights. Gel chromatography was also used by Bjelle, Andersson, and Granath,5 but they were forced to purify the HA by density gradient centrifugation before the analysis. In order to prove a change in molecular weight of HA in RA it is necessary to analyse a normal reference material by the same technique. It is evident from the fact that the human knee joint contains only a few millilitres of SF that there are both practical and ethical obstacles to the collection of material in vivo. Most studies report results from SF collected after death, which introduces the uncertainty of postmortem changes. If material is collected as soon as possible after death we believe that our results are representative of normal SF, and this conclusion is reinforced by the close similarity between our molecular weight data and those obtained by The mean value of the molecular weight of HA in joint disease is moderately although significantly lower than in normal SF (Table 2) , and our data thus confirm previous reports.14 However, it is striking that despite severe arthropathy the amount of very high molecular weight HA is considerable; as a matter of fact, in view of the total increase of HA in the joint there is more high molecular weight polysaccharide (Mw> 6 x 106) in an inflamed joint than in a normal joint. It has often been claimed that the change in rheological properties of the synovial fluid in RA is due to lack of high molecular weight HA. Our data are at variance with such an interpretation; the main cause of decreased vis-* Fig. 2 Plot of the weight-average molecular weight ofsodium hyaluronate versus logarithm ofthe volume ofsynovialfluid in the joint. The correlation coefficient r= -0-58. The volume ofthe synovialfluid of the controls was set to 15 ml. 5 1 0 50 100 500
Volume of synovial effusion (ml) coelastic behaviour must be the lower concentration of the polysaccharide.12
We found that systemic or local steroid treatment had no effect on the concentration or molecular weight of HA. Others have found a possible effect of steroids on the property of HA in SF. 13 We found no correlation between the HA concentration or the molecular weight and the clinical and laboratory parameters shown in Table 1 , except for a negative correlation between the weight-average molecular weight and the effusion volume (Fig. 2) .
High molecular weight HA has been used for local treatment in joint disease in humans and animals.1417 The rationale for this treatment has been to replace degraded HA with high molecular weight polysaccharide. Our present data show that high molecular weight HA is not lacking in the disordered joint. The therapeutic effect of injected high molecular weight HA may therefore be due to an increase in the local concentration rather than a major change in the macromolecular properties of the synovial polysaccharide.
